Latest News

COVID vaccines could lose their punch within a year, experts say


 

“Dire, but not surprising”

Panagis Galiatsatos, MD, MHS, a pulmonologist at John Hopkins University, Baltimore, whose research focuses on health care disparities, said the survey findings were “dire, but not surprising.”

Johns Hopkins was another of the centers surveyed, but Dr. Galiatsatos wasn’t personally involved with the survey.

COVID-19, Dr. Galiatsatos pointed out, has laid bare disparities, both in who gets the vaccine and who’s involved in trials to develop the vaccines.

“It’s morally concerning and an ethical reckoning,” he said in an interview.

Recognition of the borderless swath of destruction the virus is exacting is critical, he said.

The United States “has to realize this can’t be a U.S.-centric issue,” he said. “We’re going to be back to the beginning if we don’t make sure that every country is doing well. We haven’t seen that level of uniform approach.”

He noted that scientists have always known that viruses mutate, but now the race is on to find the parts of SARS-CoV-2 that don’t mutate as much.

“My suspicion is we’ll probably need boosters instead of a whole different vaccine,” Dr. Galiatsatos said.

Among the strategies sought by the People’s Vaccine Alliance is for all pharmaceutical companies working on COVID-19 vaccines to openly share technology and intellectual property through the World Health Organization COVID-19 Technology Access Pool, to speed production and rollout of vaccines to all countries.

In the survey, 74% said that open sharing of technology and intellectual property could boost global vaccine coverage; 23% said maybe and 3% said it wouldn’t help.

The survey was carried out between Feb. 17 and March 25, 2021. Respondents included epidemiologists, virologists, and infection disease specialists from the following countries: Algeria, Argentina, Australia, Belgium, Bolivia, Canada, Denmark, Ethiopia, France, Guatemala, India, Italy, Kenya, Lebanon, Norway, Philippines, Senegal, Somalia, South Africa, South Sudan, Spain, United Arab Emirates, Uganda, United Kingdom, United States, Vietnam, Zambia, and Zimbabwe.

Dr. Offit and Dr. Galiatsatos reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Infliximab weakens COVID-19 antibody response for IBD patients
MDedge Infectious Disease
COVID-19 variants now detected in more animals, may find hosts in mice
MDedge Infectious Disease
COVID-19 maternal antibodies transferred to fetus, newborn from pregnant and lactating vaccine recipients
MDedge Infectious Disease
Vitamin D may protect against COVID-19, especially in Black patients
MDedge Infectious Disease
In U.S., lockdowns added 2 pounds per month
MDedge Infectious Disease
COVID-19 vaccination in RMD patients: Safety data “reassuring”
MDedge Infectious Disease
Encephalopathy common, often lethal in hospitalized patients with COVID-19
MDedge Infectious Disease
COVID-19 ‘long-haul’ symptoms overlap with ME/CFS
MDedge Infectious Disease
New COVID-19 cases rise again in children
MDedge Infectious Disease
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
MDedge Infectious Disease